Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 8/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL715893 | 0.94 | — | — | |
| SCHEMBL5868732 | 0.81 | EPHX1 (0.33) | ALDH1A1KDM4ECA1CA2CA12 | |
| SCHEMBL4591723 | 0.79 | MTNR1A (0.34) | ALDH1A1KDM4EEPHX1EPHX2SMN1; SMN2 | |
| SCHEMBL4592222 | 0.78 | HSD11B1 (0.43) | ALDH1A1EPHX1EPHX2NPC1RAB9A | |
| SCHEMBL9674784 | 0.74 | HSD11B1 (0.41) | ALDH1A1ATMEPHX1MAPT | |
| SCHEMBL3431751 | 0.74 | BTK (0.45) | CA1CA2EPHX1 | |
| SCHEMBL4592100 | 0.72 | MTNR1A (0.35) | EPHX1EPHX2SMN1; SMN2 | |
| SCHEMBL7925 | 0.71 | L3MBTL1 (0.42) | ALDH1A1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL7384194 | 0.71 | NOS2 (0.34) | — | |
| SCHEMBL528403 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912721-B2 | Fused pentacyclic imidazole derivatives | UCB Biopharma SRL (BE) | 2024-02-27 | — | — | US | disclosed |
| EP-3740478-B1 | FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2023-11-01 | — | — | EP | disclosed |
| CN-111601799-B | Fused imidazole derivatives as Il-17 modulators | UCB生物制药有限责任公司 | 2023-06-09 | — | — | CN | disclosed |
| US-11472794-B2 | Fused imidazole derivatives as IL-17 modulators | UCB Biopharma SRL (BE) | 2022-10-18 | — | — | US | disclosed |
| US-20220227764-A1 | Imidazopyridine Derivatives as IL-17 Modulators | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2022-07-21 | — | — | US | disclosed |
| EP-3990459-A1 | IMIDAZOPYRIDINE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2022-05-04 | — | — | EP | disclosed |
| EP-3990451-A1 | FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2022-05-04 | — | — | EP | disclosed |
| CN-109195968-B | Fused pentacyclic imidazole derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2022-02-11 | — | — | CN | disclosed |
| CN-114026084-A | Fused imidazole derivatives as IL-17 modulators | UCB生物制药有限责任公司 | 2022-02-08 | — | — | CN | disclosed |
| CN-109219609-B | Fused hexacyclic imidazole derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2022-02-01 | — | — | CN | disclosed |
| WO-2007048802-A1 | (HETERO)ARYL COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | WO | disclosed |
| US-7098219-B2 | Quinolone derivatives | WOCKHART LIMITED (IN) | 2006-08-29 | — | — | US | disclosed |
| EP-1305048-A2 | INHIBITORS OF CELLULAR EFFLUX PUMPS OF MICROBES | Wockhardt Limited (IN) | 2003-05-02 | — | — | EP | disclosed |
| US-20020177559-A1 | Quinolone derivatives | WOCKHARDT LIMITED | 2002-11-28 | — | — | US | disclosed |
| WO-2002009758-A2 | INHIBITORS OF CELLULAR EFFLUX PUMPS OF MICROBES | WOCKHARDT LIMITED (IN) | 2002-02-07 | — | — | WO | disclosed |
| US-4552879-A | BACTERICIDES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1985-11-12 | — | — | US | disclosed |
| EP-0055444-B1 | TRISUBSTITUTED PYRIMIDO(5,4-D)PYRIMIDINES, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1985-03-20 | — | — | EP | disclosed |
| US-4478833-A | ANTICOAGULANTS | DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1984-10-23 | — | — | US | disclosed |
| US-4399134-A | BACTERICIDES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1983-08-16 | — | — | US | disclosed |
| EP-0055444-A2 | Trisubstituted pyrimido(5,4-d)pyrimidines, their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1982-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472794-B2 | Fused imidazole derivatives as IL-17 modulators | IL17A, IL2, IL23R | ALDH1A1 1807/4885KDM4E 1817/4885ATM 1705/4885 |
| US-20220227764-A1 | Imidazopyridine Derivatives as IL-17 Modulators | IL17A, IL2, IL23R | ALDH1A1 1119/4885KDM4E 1820/4885ATM 3086/4885 |
| US-11912721-B2 | Fused pentacyclic imidazole derivatives | TNF, NFKBIA, TNFRSF1A | ALDH1A1 367/4885KDM4E 4607/4885ATM 1903/4885 |
| US-20020177559-A1 | Quinolone derivatives | ABCB11, ABCB1, ABCG2 | ALDH1A1 2312/4885KDM4E 3354/4885ATM 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.